Literature DB >> 19530954

Dental school deans' and dentists' perceptions of infection control and HIV/AIDS patient care: a challenge for dental education in Mexico.

E E Vázquez-Mayoral1, L Sánchez-Pérez, Y Olguín-Barreto, A E Acosta-Gío.   

Abstract

HIV/AIDS patients face unique oral diagnostic and treatment challenges. The aim of this investigation among dental school deans (DSD) and graduate school applicants (GSA) who had qualified from 30 different dental schools was to assess their perceptions on dental education relevant to infection control (IC) and HIV/AIDS patient care. The questionnaire included Likert-type scale evaluations of agreement with statements. Of 158 questionnaires, 23 DSD (68% response rate), and 123 GSA (100% response rate) returned valid questionnaires. Fifteen (65%) DSD and 89 (72%) GSA ranked as "very strong" their perception that infection control prevents the transmission of blood borne viruses. However, the perception prevailed, among DSD and GSA, that HIV infection was a "very strong" to "strong" occupational hazard. Special reprocessing of instruments used on HIV patients was frequently reported. Many considered "very strong" to "strong" that HIV/AIDS patients must be treated in specialized clinics, and nearly half (48%) of the DSD and one third (35%) of the GSA stated that their school does refer HIV/AIDS patients to dental treatment in specialized clinics. These results indicate that many dental schools in Mexico must provide better education on IC and HIV/AIDS patient care to enhance attitudes toward HIV/AIDS patients.

Entities:  

Mesh:

Year:  2009        PMID: 19530954     DOI: 10.1089/apc.2008.0117

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  1 in total

1.  Dentists' Perceptions of Their SARS-CoV-2 Risk and Infection Control Needs.

Authors:  Leonor Sánchez-Pérez; Dámaris Sosa de Antuñano; Bernardo Perea-Pérez; Elena Labajo-González; A Enrique Acosta-Gio
Journal:  Int Dent J       Date:  2021-07-19       Impact factor: 2.512

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.